Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors

5 Jul 2024

Abstract excerpt

Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related therapies on the tumor microenvironment (TME) remains elusive. Our study generates single-cell gene expression and T cell receptor profiles, along with validatory multimodal datasets from >100 high-grade serous ovarian cancer (HGSOC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38971151
DOI: 10.1016/j.cell.2024.06.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsPMID 38971151Read ↗

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersSemantic proximity Read ↗

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read ↗

Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancerSemantic proximity Read ↗

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerSemantic proximity Read ↗

Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.Semantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity Read ↗

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.Semantic proximity Read ↗

PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancerSemantic proximity Read ↗

Convergent stromal and immune remodeling defines spatial tumor dynamics in PARP inhibitor–resistant high-grade serous ovarian cancerSemantic proximity Read ↗

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.